Completed PHASE2 INTERVENTIONAL 2-arm NCT00632502

Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)

Safety of SCH 527123 in Subjects With Neutrophilic Asthma

Sponsor: Merck Sharp & Dohme LLC

Interventions Navarixin Placebo Rescue medication

Updated 8 times since 2017 Last updated: Dec 10, 2018 Started: May 1, 2008 Primary completion: Feb 1, 2009 Completion: Feb 1, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Neutrophilic Asthma and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2022 [monthly]

Completed PHASE2
Feb 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Feb 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.